Novel 1,5-diphenyl-6-substituted 1H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones induced apoptosis in RKO colon cancer cells

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014;64:9–29
   PubMed Web of Science ®Google Scholar
• Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191–7
   PubMedGoogle Scholar
• Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005;52:609–27
   PubMed Web of Science ®Google Scholar
• Meier P, Vousden KH. Lucifer's labyrinth – ten years of path finding in cell death. Mol Cell 2007;28:746–54
   PubMed Web of Science ®Google Scholar
• Gupta S, Kass GE, Szegezdi E, Joseph B. The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med 2009;13:1004–33
   PubMed Web of Science ®Google Scholar
• Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009;122:437–41
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Morselli E, Kepp O, et al. Mitochondrial gateways to cancer. Mol Aspects Med 2010;31:1–20
   PubMed Web of Science ®Google Scholar
• Portt L, Norman G, Clapp C, et al. Anti-apoptosis and cell survival: a review. Biochim Biophys Acta 2011;1813:238–59
   PubMed Web of Science ®Google Scholar
• Rashad AE, Mahmoud AE, Ali MM. Synthesis and anticancer effects of some novel pyrazolo[3,4-d]pyrimidine derivatives by generating reactive oxygen species in human breast adenocarcinoma cells. Eur J Med Chem 2011;46:1019–26
   PubMed Web of Science ®Google Scholar
• Ghorab MM, Ragab FA, Alqasoumi SI, et al. Synthesis of some new pyrazolo[3,4-d]pyrimidine derivatives of expected anticancer and radioprotective activity. Eur J Med Chem 2010;45:171–8
   PubMed Web of Science ®Google Scholar
• Kumar A, Ahmad I, Chhikara BS, et al. Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. Bioorg Med Chem Lett 2011;21:1342–6
   PubMed Web of Science ®Google Scholar
• Hassan GS, Kadry HH, Abou-Seri SM, et al. Synthesis and in vitro cytotoxic activity of novel pyrazolo[3,4-d]pyrimidines and related pyrazole hydrazones toward breast adenocarcinoma MCF-7 cell line. Bioorg Med Chem Lett 2011;19:6808–17
   Web of Science ®Google Scholar
• Abd El Hamid MK, Mihovilovic MD, El-Nassan HB. Synthesis of novel pyrazolo[3,4-d]pyrimidine derivatives as potential anti-breast cancer agents. Eur J Med Chem 2012;57:323–8
   PubMed Web of Science ®Google Scholar
• Kim DC, Lee YR, Yang B, et al. Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors. Eur J Med Chem 2003;38:525–32
   PubMed Web of Science ®Google Scholar
• Traxler P, Bold G, Frei J, et al. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997;40:3601–16
   PubMed Web of Science ®Google Scholar
• Indovina P, Giorgi F, Rizzo V, et al. New pyrazolo[3,4-d]pyrimidine Src inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene 2012;31:929–38
   PubMed Web of Science ®Google Scholar
• Carraro F, Naldini A, Pucci A, et al. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem 2006;49:1549–61
   PubMed Web of Science ®Google Scholar
• Santucci MA, Corradi V, Mancini M, et al. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. Chem Med Chem 2009;4:118–126
   Web of Science ®Google Scholar
• Radi M, Dreassi E, Brullo C, et al. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. . J Med Chem 2011;54:2610–26
   PubMed Web of Science ®Google Scholar
• Richard DJ, Verheijen JC, Curran K, et al. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorg Med Chem Lett 2009;19:6830–5
   PubMed Web of Science ®Google Scholar
• Markwalder JA, Arnone MR, Benfield PA, et al. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclindependent kinases. J Med Chem 2004;47:5894–911
   PubMed Web of Science ®Google Scholar
• El-Enany MM, Kamel MM, Khalil OM, El-Nassan HB. Synthesis and antitumor activity of novel 6-aryl and 6-alkylpyrazolo[3,4-d]pyrimidin-4-one derivatives. Eur J Med Chem 2010;45:5286–91
   PubMed Web of Science ®Google Scholar
• Rostom SAF, Ashour HMA, Abd ElRazik HA. Synthesis and biological evaluation of some novel polysubstituted pyrimidine derivatives as potential antimicrobial and anticancer agents. Arch Pharm Chem Life Sci 2009;342:299–310
   PubMed Web of Science ®Google Scholar
• Ashour HMA, Abdel Wahab AE. Synthesis and biological evaluation of novel pyrazoles and pyrazolo[3,4-d]pyrimidines incorporating a benzenesulfonamide moiety. Arch Pharm Chem Life Sci 2009;342:238–52
   PubMed Web of Science ®Google Scholar
• Rostom SAF, Badr MH, Abd ElRazik HA, et al. Synthesis of some pyrazolines and pyrimidines derived from polymethoxy chalcones as anticancer and antimicrobial agents. Arch Pharm Chem Life Sci 2011;344:572–87
   PubMed Web of Science ®Google Scholar
• Malki A, Elbayaa RY, Ashour HMA, et al. Novel thiosemicarbazides induced apoptosis in human MCF-7 breast cancer cells via JNK signaling. J Enzyme Inhib Med Chem 2015;30:786–95
   PubMed Web of Science ®Google Scholar
• Ibrahim DA, El-Metwally AM. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem 2010;45:1158–66
   PubMed Web of Science ®Google Scholar
• Zhang H-Z, Crogan-Grundy C, May C, et al. Discovery and structure–activity relationships of (2-(arylthio)benzylideneamino)guanidines as a novel series of potent apoptosis inducers. Bioorg Med Chem Lett 2009;17:2852–8
   Web of Science ®Google Scholar
• Andreani A, Granaiola M, Leoni A, et al. Potential antitumor agents. 37.1 Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from the new heterocyclic system thiazolo[2′,3′:2,3]imidazo[4,5-c]quinoline. J Med Chem 2005;48:3085–9
   PubMed Web of Science ®Google Scholar
• Andreani A, Burnelli S, Granaiola M, et al. New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues. J Med Chem 2008;51:809–16
   PubMed Web of Science ®Google Scholar
• Zhang H, Drewe J, Tseng B, et al. Discovery and SAR of indole-2-carboxylic acid benzylidenehydrazides as a new series of potent apoptosis inducers using a cell based HTS assay. Bioorg Med Chem 2004;12:3649–55
   PubMed Web of Science ®Google Scholar
• Cocco MT, Congiu C, Lilliu V, Onnis V. Synthesis and in vitro antitumoral activity of new hydrazinopyrimidine-5-carbonitrile derivatives. Bioorg Med Chem 2005;14:366–72
   PubMed Web of Science ®Google Scholar
• Rollas S, Küçükgüzel G. Biological activities of hydrazone derivatives. Molecules 2007;12:1910–39
   PubMed Web of Science ®Google Scholar
• Nasr T, Bondock S, Youns M. Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. Eur J Med Chem 2014;76:539–48
   PubMed Web of Science ®Google Scholar
• Baviskar AT, Banerjee UC, Gupta M, et al. Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity. Bioorg Med Chem 2013;21:5782–93
   PubMed Web of Science ®Google Scholar
• Peet NP, Lentz NL, Sunder S, et al. Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors. J Med Chem 1992;35:3263–9
   PubMed Web of Science ®Google Scholar
• Garin J, Loscertales MP, Melendez E, et al. Methyl N-aryldithiocarbamates: useful reagents for the annelation of pyrimidines and 1,3-oxazines to five-membered heterocyclic rings. Heterocycles 1987;26:1303–12
   Web of Science ®Google Scholar
• Shaaban MA, Abou Sier AH, El-Ansary AK, et al. Synthesis and pharmacological activities of certain pyrazolotriazolopyrimidine and pyrazolotriazepine derivatives. Bull Facul Pharm (Cairo Univ) 2001;39:67–77
   Google Scholar
• Trost BM, Curran DP. Chemoselective oxidation of sulfides to sulfones using potassium hydrogenpersulfate. Tetr Lett 1981;22:1287–90
   Web of Science ®Google Scholar
• Lin CF, Yang JS, Chang CY, et al. Synthesis and anticancer activity of benzyloxybenzaldehyde derivatives against HL-60 cells. Bioorg Med Chem 2005;13:1537–44
   PubMed Web of Science ®Google Scholar
• Barboni L, Giarlo G, Ballini R, Fontana G. 14Beta-hydroxy-10-deacetylbaccatin III as a convenient, alternative substrate for the improved synthesis of methoxylated second-generation taxanes. Bioorg Med Chem Lett 2006;16:5389–91
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51
   PubMed Web of Science ®Google Scholar
• Shrivastava HY, Ravikumar T, Shanmugasundaram N, et al. Cytotoxicity studies of chromium(III) complexes on human dermal fibroblasts. . Free Radic Biol Med 2005;38:58–69
   PubMed Web of Science ®Google Scholar
• Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis – the p53 network. J Cell Sci 2003;116:4077–85
   PubMed Web of Science ®Google Scholar
• Taguchi T, Kato Y, Baba Y, et al. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol Rep 2004;11: 421–46
   PubMed Web of Science ®Google Scholar
• Pellecchia M, Reed JC. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Curr Pharm Des 2004;10:1387–98
   PubMed Web of Science ®Google Scholar
• Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147–57
   PubMed Web of Science ®Google Scholar